CTRI/2023/01/049182尚未招募3 期
A phase 3 randomized controlled study evaluating the efficacy of scalp cooling in patients undergoing systemic therapy - None
Cancer Research and Statistics Foundatiion0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects must be planned for either taxane-based or anthracycline-based chemotherapy regimens.
- •2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3.
- •3. Subjects must have normal organ and marrow function.
- •4. Willing and able to comply with all study requirements, including treatment, able to be follow-up at regular intervals, and/or nature of required assessments.
- •5. Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •1. Subjects who have preexisting alopecia.
- •2. Within 3 weeks of administration of a chemotherapeutic agent.
- •3. An active autoimmune disease that may contribute to the development of alopecia when receiving a chemotherapeutic agent.
- •4. Pregnant and lactating women are excluded from this study.
- •5. Local site infection making it infeasible for use of a scalp cooling device.
- •6. Subjects with cold agglutinin disease or cryoglobulinemia or post-traumatic cold dystrophy.
研究者
相似试验
尚未招募
3 期
CARG risk score based chemotherapy in older patients with advanced GI cancers phase III trialCTRI/2022/03/040884Tata Memorial Hospital
进行中（未招募）
不适用
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-NLJanssen-Cilag International N.V.240
进行中（未招募）
不适用
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-BEJanssen-Cilag International N.V.240
进行中（未招募）
不适用
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-PLJanssen-Cilag International N.V.240
进行中（未招募）
1 期
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2011-004795-11-DEJanssen-Cilag International N.V.240